TB Diagnostic Technologies

· TB Diagnostic Technologies and Hospital Impact

• Medical Center A in Taipei transitioned to auramine-rhodamine staining from Ziehl-Neelsen staining by 2014, aiming to improve TB detection and patient isolation.
• Enhanced diagnostic sensitivity resulted in doubling the positive sputum smear rate from 22.8% to 48.1%, especially for non-cavitary lung lesions.
• The median duration of non-isolated infectiousness reduced significantly from 12.5 days to 3 days, and the total number of non-isolated infectious patient-days decreased by 69% from 2001 to 2014.
• Suggestion: Implement continuous training for healthcare staff on the latest TB diagnostic technologies to maintain high detection rates and reduce the time to isolation.

· Risk Factors and Control Measures in Healthcare Settings

• Inadequate ventilation and insufficient environmental cleaning in healthcare settings heighten TB transmission risks.
• Frequent healthcare visits are closely linked to increased TB incidence, necessitating robust infection control measures in high-traffic areas like internal medicine and family medicine.
• Suggestion: Prioritize the installation of germicidal ultraviolet systems and upgraded ventilation in outpatient areas to minimize airborne transmission.

· Epidemiological Insights and Trends

• TB incidence and related mortality have declined in younger populations (<20 and 20–50 years) in mainland China, reflecting effective control measures.
• However, SS- TB cases and mortality in the >50 age group remained high, indicating ongoing vulnerabilities.
• Suggestion: Develop targeted health campaigns and screening programs focused on the elderly to address the persistently high TB rates in this demographic.

· Regional and Systemic Challenges in Taiwan

• Increased Health System Delay (HSD) in diagnosing TB was noted between 2003 and 2008, influenced by factors such as patient’s age, gender, and the type of health facility visited.
• Eastern Taiwan showed shorter HSDs due to a higher concentration of TB-specialized providers, while medical centers experienced longer delays.
• Suggestion: Enhance the distribution and accessibility of specialized TB healthcare services across different regions to ensure timely diagnosis and treatment.

· Link Between TB and Chronic Conditions

• Tuberculosis is a significant risk factor for developing chronic obstructive pulmonary disease (COPD), with risks increasing due to delays in TB treatment initiation.
• Early diagnosis and timely treatment of TB are crucial to mitigate COPD risk.
• Suggestion: Strengthen the integration of TB and COPD management protocols to improve patient outcomes and reduce the incidence of COPD among former TB patients.

See also: https://lintblab.weebly.com

References:

1. Sun H-Y, Wang J-Y, Chen Y-C, Hsueh PR, Chen Y-H, Chuang Y-C, et al. (2020) Impact of introducing fluorescent microscopy on hospital tuberculosis control: A before-after study at a high caseload medical center in Taiwan. PLoS ONE 15(4): e0230067.
2. Pan, S.C., Chen, C.C., Chiang, Y.T., Chang, H.Y., Fang, C.T. and Lin, H.H., 2016. Health care visits as a risk factor for tuberculosis in Taiwan: a population-based case–control study. American journal of public health, 106(7), pp.1323-1328.
3. Liu, K.H., Xiao, Y.X. and Jou, R., 2024. Multidrug-resistant tuberculosis clusters and transmission in Taiwan: a population-based cohort study. Frontiers in Microbiology, 15, p.1439532.
4. Huang, F. and Bello, S.T., 2024. Spatiotemporal analysis of regional and age differences in tuberculosis prevalence in mainland China. Tropical Medicine & International Health, 29(9), pp.833-841.
5. Fu, H., Lin, HH., Hallett, T.B. et al. Explaining age disparities in tuberculosis burden in Taiwan: a modelling study. BMC Infect Dis 20, 191 (2020).
6. Chen, C.C., Chiang, C.Y., Pan, S.C., Wang, J.Y. and Lin, H.H., 2015. Health system delay among patients with tuberculosis in Taiwan: 2003–2010. BMC infectious diseases, 15, pp.1-9.
7. Lee C-H, Lee M-C, Lin H-H, Shu C-C, Wang J-Y, et al. (2012) Pulmonary Tuberculosis and Delay in Anti-Tuberculous Treatment Are Important Risk Factors for Chronic Obstructive Pulmonary Disease. PLoS ONE 7(5): e37978.

TBC 036

Interaction between DM and TB exacerbates disease progression

Public Health Challenges and Epidemiology: Tuberculosis (TB) presents varying challenges across economic contexts. Rapid diagnosis and treatment are essential in regions with high TB prevalence to manage and prevent the disease, primarily through addressing the reactivation of latent TB infections (LTBI). In areas with lower incidence, TB tends to concentrate within high-risk groups, necessitating strategies tailored to local epidemiological patterns and social determinants. Additionally, understanding the demographic shifts towards older populations and the impact of diabetes mellitus (DM) on TB, including increased risk and poorer outcomes, is crucial.

Impact of Diabetes on Tuberculosis: Diabetes significantly increases the risk of developing active TB and affects treatment outcomes. The interaction between DM and TB exacerbates disease progression, with DM patients experiencing higher mycobacterial loads and unique lung lesions. This underscores the importance of integrated health strategies that simultaneously address both TB and DM, including enhanced screening and research into the transmission dynamics among these patients.

Study Insights and Special Populations:

• A study in metro Atlanta, Georgia (2016-2019) on HIV-negative adults with type 2 diabetes (T2DM) highlighted that LTBI was less prevalent in diabetic patients compared to controls. This suggests unique interplays between T2DM and LTBI, impacting screening and management approaches.
• The WHO emphasizes LTBI screening in populations with compromised immune systems, such as those undergoing dialysis or with chronic kidney disease (CKD), due to elevated TB risk.

Health Outcomes and Quality of Life in TB Survivors: TB survivors face considerable health challenges, including increased risks of TB recurrence and mortality. Chronic conditions such as respiratory diseases and cardiovascular issues are more prevalent among these individuals, leading to diminished quality of life and increased healthcare needs. Social and economic repercussions include stigma and financial hardship, emphasizing the need for comprehensive healthcare strategies that integrate TB care with broader health services to manage ongoing issues and improve life quality.

Epidemiological and Clinical Integration: The convergence of TB and DM epidemics, especially in regions like South-East Asia, the Western Pacific, and the Middle East, driven by rising rates of diabetes due to obesity and aging populations, calls for integrated public health responses. These should consider the compounded effects of both diseases on mortality, treatment failure, and relapse rates.

Advancements in Screening and Treatment: Advancements in technology and healthcare strategies, such as single-cell analysis and predictive modeling, hold promise for enhancing the understanding and management of TB-DM comorbidity. These tools can help in identifying new therapeutic targets and biomarkers, improving the precision of diagnostics and treatments.

Comprehensive Care for TB Survivors: Addressing the long-term health effects faced by TB survivors requires a multifaceted approach that includes lung function evaluations, pulmonary rehabilitation, and cardiovascular care. Economic support and social integration programs are also vital to mitigate the socio-economic impacts of TB on survivors and their families.

References:

1. Lee, P.H., Fu, H., Lee, M.R., Magee, M. and Lin, H.H., 2018. Tuberculosis and diabetes in low and moderate tuberculosis incidence countries. The International Journal of Tuberculosis and Lung Disease, 22(1), pp.7-16.
2. Salindri, A.D., Haw, J.S., Amere, G.A., Alese, J.T., Umpierrez, G.E. and Magee, M.J., 2021. Latent tuberculosis infection among patients with and without type-2 diabetes mellitus: results from a hospital case-control study in Atlanta. BMC Research Notes, 14(1), p.252.
3. Zhang, X., Chen, P. and Xu, G., 2022. Update of the mechanism and characteristics of tuberculosis in chronic kidney disease. Wiener klinische Wochenschrift, 134(13), pp.501-510.
4. Kaur, R., Egli, T., Paynter, J., Murphy, R., Perumal, L., Lee, A., Harrison, A., Christmas, T., Lewis, C. and Nisbet, M., 2023. Tuberculosis and diabetes: increased hospitalisations and mortality associated with renal impairment. Internal Medicine Journal, 53(9), pp.1588-1594.
5. Choi, H., Han, K., Jung, J.H., Park, S.H., Kim, S.H., Kang, H.K., Sohn, J.W., Shin, D.W. and Lee, H., 2023. Long-term mortality of tuberculosis survivors in Korea: a population-based longitudinal study. Clinical Infectious Diseases, 76(3), pp.e973-e981. See also: https://tbreadingnotes.blogspot.com/2024/07/non-communicable-diseases-in-tb.html
6. Dodd, P.J., Yuen, C.M., Jayasooriya, S.M., van der Zalm, M.M. and Seddon, J.A., 2021. Quantifying the global number of tuberculosis survivors: a modelling study. The Lancet Infectious Diseases, 21(7), pp.984-992.

TBC 033

Link Between Diabetes and Tuberculosis: Risks, Outcomes, and Key Insights

Diabetes mellitus (DM) significantly increases the risk of developing active tuberculosis (TB), with affected individuals being 2–3 times more likely to contract the disease. Additionally, TB patients with DM face poorer treatment outcomes compared to those without DM, including lower cure rates and increased mortality. Dysglycemia, encompassing both DM and prediabetes, plays a critical role in shaping TB disease presentation. Among pulmonary TB (PTB) patients, dysglycemia prevalence at baseline was 61.4%, with 47.1% classified as prediabetes and 14.3% as DM. These patients frequently presented with more severe manifestations, including a higher prevalence of cavitary disease and extensive lung involvement on chest X-rays (CXR). See also: https://lintblab.weebly.com/profile.html

Patients with dysglycemia demonstrated significantly more advanced disease characteristics compared to their normoglycemic counterparts. For instance, cavitary disease was observed in 80.2% of dysglycemic patients versus 63.0% in normoglycemic TB (NGTB) patients, while bilateral lung lesions were more common (67.4% vs. 46.0%). Dysglycemic patients also had a greater median number of affected lung thirds (3 vs. 2). Sputum smear positivity rates were notably higher in the prediabetes and DM groups (93.0%) compared to NGTB patients (75.9%), further highlighting the aggressive disease course in dysglycemic individuals. However, resistant M. tuberculosis strains were more frequently detected in NGTB (20.9%) and prediabetes (19.0%) groups compared to DM (10.0%), suggesting differences in pathogen dynamics.

A South Korean study explored the broader implications of DM on TB through retrospective and cohort analyses. In newly diagnosed type 2 DM patients, the TB incidence rate was 3.7 per 1,000 individuals, with regional variations. In another study on multidrug-resistant TB (MDR-TB), 17% of patients also had DM. These patients faced worse outcomes, with treatment success rates significantly lower (36.0%) than those without DM (47.2%). DM was identified as an independent predictor of poor outcomes, alongside other factors such as low BMI and extensively drug-resistant TB (XDR-TB).

Further investigation into the Korean TB-POST cohort revealed a co-prevalence of DM in 26.8% of TB patients, with 12.5% developing new-onset diabetes (nDM) following TB diagnosis. Co-prevalence increased with age, particularly among men and those with lower incomes. New-onset diabetes patients were generally younger and exhibited more advanced TB at diagnosis, often with positive acid-fast bacilli (AFB) smears. These findings underscore the bidirectional relationship between TB and diabetes, with each condition exacerbating the severity and treatment challenges of the other.

Prediabetes, a precursor to DM, is also linked to unfavorable TB outcomes. A pooled analysis of eight cohort studies found that 25.1% of TB patients had prediabetes, which was associated with a higher incidence of treatment failure, recurrence, and other adverse outcomes. However, no significant increase in all-cause mortality was observed. These findings emphasize the urgent need for prospective studies to unravel the complex interplay between dysglycemia and TB, particularly in high-burden settings, and to guide tailored interventions for this high-risk population. See also: https://tbreadingnotes.blogspot.com/2024/10/glycemic-control-in-tuberculosis-tb0090.html

References:

1. Bezerra, A.L., Moreira, A.D.S.R., Isidoro-Gonçalves, L., Lara, C.F.D.S., Amorim, G., Silva, E.C., Kritski, A.L. and Carvalho, A.C.C., 2022. Clinical, laboratory, and radiographic aspects of patients with pulmonary tuberculosis and dysglycemia and tuberculosis treatment outcomes. Jornal Brasileiro de Pneumologia, 48(06), p.e20210505.
2. Yang, B.R., Kang, Y.A., Heo, E.Y., Koo, B.K., Choi, N.K., Hwang, S.S. and Lee, C.H., 2018. Regional differences in the incidence of tuberculosis among patients with newly diagnosed diabetes mellitus. The Clinical Respiratory Journal, 12(4), pp.1732-1738.
3. Kang, Y.A., Kim, S.Y., Jo, K.W., Kim, H.J., Park, S.K., Kim, T.H., Kim, E.K., Lee, K.M., Lee, S.S., Park, J.S. and Koh, W.J., 2014. Impact of diabetes on treatment outcomes and long-term survival in multidrug-resistant tuberculosis. Respiration, 86(6), pp.472-478.
4. Jeong D, et al. Prevalence and associated factors of diabetes mellitus among patients with tuberculosis in South Korea from 2011 to 2018: a nationwide cohort study. BMJ Open 2023;13:e069642.
5. Liang, L. and Su, Q., 2024. Prediabetes and the treatment outcome of tuberculosis: A meta‐analysis. Tropical Medicine & International Health, 29(9), pp.757-767.

TBC 029

Clinical Challenges and Management Strategies for TB-DM

• TB and Glucose Metabolism: TB can lead to impaired glucose tolerance, which might normalize after treatment but increases the risk for T2DM due to stress, inflammation, and metabolic changes. See also: https://lintblab.weebly.com/group-members.html
• Hyperglycemia in TB: Hyperglycemia is common in TB patients (10-26% prevalence), resulting from systemic inflammation and altered metabolism.
• Immunometabolic Impact: TB causes significant changes like increased inflammation, altered adipose tissue function, and elevated free fatty acids, contributing to insulin resistance (IR).
• Lipid Dysregulation: TB infection increases free fatty acids, leading to high LDL, low HDL, high VLDL, and ectopic fat deposition in organs, promoting IR.
• TB-DM Co-occurrence: When TB and diabetes coexist, it complicates treatment, potentially leading to drug resistance and poorer outcomes.
• Impact on TB Treatment: Diabetes negatively affects TB treatment success, increasing mortality, failure rates, and loss to follow-up.
• Immune Deficiency in Diabetes: Diabetes compromises immune function, reducing TB control by impairing macrophage activity, cytokine release, and T-cell responses.
• Altered Immune Response in Latent TB: Diabetic patients with latent TB exhibit heightened inflammatory responses, suggesting altered immune signaling.
• Clinical Management: Integrated management of TB and DM/IR is necessary to prevent diabetes progression and improve TB outcomes.
• HbA1c Monitoring: Regular HbA1c monitoring during TB treatment helps identify individuals at risk for poor outcomes due to hyperglycemia.
• Diabetes Treatment: Effective diabetes management in TB patients leads to better clinical outcomes, reducing TB severity and complications.
• Symptom Severity: TB in diabetic patients often results in more severe symptoms, correlated with higher HbA1c levels.
• Cardiovascular Complications: TB increases the risk of cardiovascular diseases through metabolic and inflammatory pathways.
• CVD Risk Management: Screening for CVD risk factors and promoting lifestyle changes are crucial in TB patients to manage cardiovascular health.
• Interdisciplinary Approach: The management of TB alongside conditions like CVD and diabetes needs cross-specialty collaboration for optimal patient care.

References:

1. Pardeshi, G., Mave, V., Gaikwad, S., Kadam, D., Barthwal, M., Gupte, N., Atre, S., Deshmukh, S., Golub, J.E. and Gupte, A., 2024. Glycated Hemoglobin Trajectories and Their Association With Treatment Outcomes Among Patients With Pulmonary TB in India: A Prospective Cohort Study. Chest, 165(2), pp.278-287.
2. Chiang CY, Bai KJ, Lin HH, Chien ST, Lee JJ, Enarson DA, et al. (2015) The Influence of Diabetes, Glycemic Control, and Diabetes-Related Comorbidities on Pulmonary Tuberculosis. PLoS ONE 10(3): e0121698. doi:10.1371/journal. pone.0121698.
3. Bisht MK, Dahiya P, Ghosh S and Mukhopadhyay S (2023) The cause-effect relation of tuberculosis on incidence of diabetes mellitus. Front. Cell. Infect. Microbiol. 13:1134036. https://tbreadingnotes.blogspot.com/2024/11/the-cause-effect-relation-of-tb-on.html
4. Basham CA, Smith SJ, Romanowski K, Johnston JC (2020). Cardiovascular morbidity and mortality among persons diagnosed with tuberculosis: A systematic review and meta-analysis. PLoS ONE, 15(7), e0235821.
5. Shabil, M., Bushi, G., Beig, M.A., Rais, M.A., Ahmed, M. and Padhi, B.K., 2023. Cardiovascular manifestation in tuberculosis cases: a systematic review and meta-analysis. Current Problems in Cardiology, 48(7), p.101666.

TBC 027